Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.

Atopic dermatitis increases the risk of some autoimmune diseases.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

Topical corticosteroids are the best initial treatment for children's alopecia areata.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

The convention highlighted the importance of comprehensive patient care and early diagnosis in dermatology.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Finasteride helps female-pattern hair loss.

A medication for skin rash also unexpectedly treated hair loss in a patient.

COVID-19 can cause skin problems and affect dermatology treatments, with recommendations for skin care and cautious use of certain drugs.

Baricitinib successfully treated severe hair loss.

JAK inhibitors may help treat alopecia areata and promote hair regrowth.

Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.

Hair loss is common in autoimmune diseases and can be an early sign of the condition, often requiring prompt treatment to prevent permanent damage.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Tofacitinib is an effective and safe treatment for alopecia areata.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.